Vitiligo

What is vitiligo and how is it managed on dark skin?

  • Tier B moderate Tested, but not in people like you
  • Last checked
  • Not yet clinically reviewed

The answer

Vitiligo is loss of skin colour in patches, an autoimmune condition, not an infection. Patches are usually permanent, though treatment can bring back colour in some people: a prescription cream did in trials, with responses seen across skin types (not compared type by type). Pale patches burn more easily, so use sunscreen. Camouflage cream can cover them.

Do

  • See a doctor for diagnosis: they may use a Wood's lamp, a UV lamp that makes patches easier to see.Clinical guidance NHS, "Vitiligo"
  • Use a high SPF sunscreen on pale patches: they are more vulnerable to sunburn.Clinical guidance NHS, "Vitiligo"
  • Try skin camouflage cream if you want to cover small patches.Clinical guidance NHS, "Vitiligo"
  • Ask about treatment if the patches are severe or making you unhappy.Clinical guidance NHS, "Vitiligo"

Avoid

  • Expecting patches to return to normal by themselves: they are usually permanent.Clinical guidance NHS, "Vitiligo"
  • Leaving pale patches unprotected in strong sun.Clinical guidance NHS, "Vitiligo"
  • Treating pale patches yourself as a fungal infection before a doctor confirms: vitiligo can be mistaken for conditions such as pityriasis versicolor, a fungal pigment loss.Clinical guidance NHS, "Vitiligo"

What families do

Tradition and common belief, not evidence.

Vitiligo is often feared as an infection or taken as a curse or a fault; in dark skin the patches are very visible and can cause distress.

The evidence

The UK's NHS says the white patches are usually permanent but treatments can reduce their appearance, and recommends a high SPF on pale patches. In two trials of 674 people, about three in ten on a ruxolitinib cream reached the main target at 24 weeks against about one in ten on vehicle; a pooled analysis said responses were observed across Fitzpatrick types, without per-type numbers in the abstract. The BAD says vitiligo affects men and women of all ethnicities equally but may have a greater impact on people of colour because it is more noticeable. A 2024 registry study in the research file found Black participants were under-represented in vitiligo trials.

This tier rests on: That a prescription cream repigments some vitiligo: two phase 3 trials of 674 people, with responses described across Fitzpatrick skin types in a pooled descriptive analysis (50.3% reached F-VASI75 at week 52; no per-type numbers in the abstract); how many Black people were included is not stated in the abstracts.

Why this tier and strength: Fact-check 12 Nov: wording now says responses were observed across skin types (descriptive), not similar benefit; the trials were manufacturer-sponsored. Tested in a mixed population; Black-specific results not found in the abstracts. Tier unchanged.

What has been tested

  1. B 674 people aged 12 or over with nonsegmental vitiligo in North America and Europe (two trials); how many were Black is not in the abstract (n=674)

    Two phase 3, randomised, double-blind, vehicle-controlled trials of 1.5% ruxolitinib cream twice daily for 24 weeks.

    At week 24, 29.8% (trial 1) and 30.9% (trial 2) on ruxolitinib cream reached a 75% improvement in facial vitiligo score, against 7.4% and 11.4% on vehicle.

    Rosmarin D, Passeron T, Pandya AG et al (2022), New England Journal of Medicine, [primary] Open source Study page

    Note: Industry-sponsored. A prescription medicine.

  2. B The same 674 patients, pooled post hoc (n=674)

    Subgroup analysis by age, sex, Fitzpatrick skin type and other traits.

    At week 52, 50.3% of those applying ruxolitinib cream throughout reached the facial score target; responses were seen across subgroups including Fitzpatrick skin type. The abstract gives no numbers for dark skin types.

    Seneschal J, Wolkerstorfer A, Desai SR et al (2025), Dermatology and Therapy, [primary] Open source Study page

    Note: Descriptive, post hoc; not a Black-population analysis.

Harm

No signal found: Pale patches burn more easily (NHS in the UK); the cream is a prescription medicine with side effects not summarised here.

Measured variables

  • Skin pigmentation (depigmentation visible against dark skin)
  • Facial vitiligo area score
  • Fitzpatrick type in subgroups

Not tested, and gaps

Untested or not found: trial results reported by Black participants specifically; non-prescription treatments, light therapy and surgical options (not opened); the psychological effects in dark skin, where I only have the BAD statement. Funding: manufacturer-sponsored trials.

All sources

  • Rosmarin D et al (2022), New England Journal of Medicine, [primary] Open
  • Seneschal J et al (2025), Dermatology and Therapy, [primary] Open
  • NHS, "Vitiligo", [official], practical advice (clinical guidance), opened 2026-11-12 Open

Common questions

What is vitiligo and how is it managed on dark skin?

Vitiligo is loss of skin colour in patches, an autoimmune condition, not an infection.

Is vitiligo contagious?

Vitiligo is loss of skin colour in patches, an autoimmune condition, not an infection.

Can vitiligo be treated?

Vitiligo is loss of skin colour in patches, an autoimmune condition, not an infection.

Last checked against its sources: . Next check due: 12 May 2027.

This is information, not medical advice. If you are worried, see a doctor or pharmacist. How we grade the evidence.